CO5271671A1 - Composicion para el tratamiento de tejidos danados - Google Patents

Composicion para el tratamiento de tejidos danados

Info

Publication number
CO5271671A1
CO5271671A1 CO00097188A CO00097188A CO5271671A1 CO 5271671 A1 CO5271671 A1 CO 5271671A1 CO 00097188 A CO00097188 A CO 00097188A CO 00097188 A CO00097188 A CO 00097188A CO 5271671 A1 CO5271671 A1 CO 5271671A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical agent
growth factor
agent according
pdgf
composition
Prior art date
Application number
CO00097188A
Other languages
English (en)
Inventor
Jonathan Paul Huggins
Nicholas Laurence Occleston
Stuart Mcintosh Fraser
Michael John Davies
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO5271671A1 publication Critical patent/CO5271671A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Un agente farmacéutico que comprende una composición que comprende: (a) Un factor de crecimiento; (b) un agente inhibidor; y, opcionalmente, (c) un vehículo, diluyente o excipiente farmacéuticamente aceptable; en el que el agente inhibidor puede inhibir la acción de al menos una proteína adversa específica (por ejemplo, una proteasa específica) que está regulada positivamente en un entorno de tejido dañado, por ejemplo, una herida. Un agente farmacéutico de acuerdo con la reivindicación 1, en el que dicho factor de crecimiento se selecciona entre uno o más de Chrysalin, VEGF, EGF, PDGF, FGF, CTGF, KGF, TGF, CSF o variantes activas, homólogos, derivados o fragmentos de los mismos. Un agente farmacéutico de acuerdo con la reivindicación 2, en el que dicho factor de crecimiento se selecciona entre uno o más de Chrysalin, VEGF, EGF, PDGF, FGF, agentes semejantes a CTGF, KGF-2, TGF-ß, GM-CSF o variantes activas, homólogos, derivados o fragmentos de los mismos. Un agente farmacéutico de acuerdo con una cualquiera de las reivindicaciones 1 a 3, en el que dicho factor de crecimiento es al menos PDGF, o una variante activa, homólogo, derivado o fragmento del mismo. Un agente farmacéutico de acuerdo con una cualquiera de las reivindicaciones 1 a 4, en que dicho agente inhibidor es un I:uPA y/o un I:MMP.
CO00097188A 1999-12-29 2000-12-21 Composicion para el tratamiento de tejidos danados CO5271671A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930768.8A GB9930768D0 (en) 1999-12-29 1999-12-29 Composition

Publications (1)

Publication Number Publication Date
CO5271671A1 true CO5271671A1 (es) 2003-04-30

Family

ID=10867127

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00097188A CO5271671A1 (es) 1999-12-29 2000-12-21 Composicion para el tratamiento de tejidos danados

Country Status (12)

Country Link
EP (1) EP1242120A2 (es)
JP (1) JP2003519193A (es)
AR (1) AR027122A1 (es)
AU (1) AU1878201A (es)
CA (1) CA2395487A1 (es)
CO (1) CO5271671A1 (es)
EC (1) ECSP003859A (es)
GB (1) GB9930768D0 (es)
GT (1) GT200000224A (es)
PE (1) PE20011095A1 (es)
UY (1) UY26514A1 (es)
WO (1) WO2001049309A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ES2304401T3 (es) 2000-10-16 2008-10-16 Genentech, Inc. Metodos de tratamiento que utilizan polipeptidos wisp.
DK1414487T3 (da) 2001-07-27 2006-10-09 Orthologic Corp Anvendelse af thrombin-peptidderivater til behandling af kroniske hudsår
WO2003029819A1 (fr) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Procede pour le criblage preventif / le traitement des maladies d'os ou d'articulations
JP2006514822A (ja) 2002-07-02 2006-05-18 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム トロンビンペプチド誘導体
ATE357928T1 (de) 2003-12-31 2007-04-15 Orthologic Corp Pharmazeutische zusammensetzung für thrombinpeptidderivaten
ES2370040T3 (es) 2005-10-07 2011-12-12 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Vacuna de metaloproteinasa 11 de la matriz.
CN101965193A (zh) * 2006-11-15 2011-02-02 科达治疗公司 用于伤口愈合的改进方法和组合物
KR101629504B1 (ko) * 2014-04-14 2016-06-10 주식회사 엘지생활건강 사이토카인 조합을 함유하는 피부 상태 개선용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279840A (ja) * 1988-04-28 1989-11-10 Wakunaga Pharmaceut Co Ltd 新規外用組成物
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
CA2395487A1 (en) 2001-07-12
AU1878201A (en) 2001-07-16
GT200000224A (es) 2002-06-15
PE20011095A1 (es) 2001-10-27
ECSP003859A (es) 2002-09-27
EP1242120A2 (en) 2002-09-25
GB9930768D0 (en) 2000-02-16
UY26514A1 (es) 2001-07-31
JP2003519193A (ja) 2003-06-17
WO2001049309A2 (en) 2001-07-12
AR027122A1 (es) 2003-03-12
WO2001049309A3 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
CO5271671A1 (es) Composicion para el tratamiento de tejidos danados
ECSP034493A (es) Inhibidores de proteasa peptidomimeticos
AR092919A2 (es) Composicion farmaceutica liquida
ATE180479T1 (de) Sulfonat- und carbamatderivate von 3-aroyl- benzo(beta)thiophenen
DK1676579T3 (da) Anvendelse af sub-antimikrobielle tetracykliner til behandling af okulær rosacea
DK0750618T3 (da) Oxazolidinonderivater og farmaceutiske præparater indeholdende dem
AR009243A1 (es) Composicion para la lucha contra las miasis de bovinos y ovinos
HUP0001964A2 (hu) Adenovírus-vektorok többszörös alkalmazása angiogenezis indukálása érdekében
ES2458493T8 (es) Composición oftálmica tópica de fluprostenol para el tratamiento del glaucoma y de la hipertensión ocular
MX9304432A (es) Compuestos y formulaciones farmaceuticas para el tratamiento o prevencion de la osteoporosis y la perdida de los huesos.
BR0209468A (pt) Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar
DK0677289T3 (da) Farmaceutisk præparat til behandling af osteoporose
ATE212846T1 (de) Bisphosphonat und anti-resorption agentien, enthaltende zusammensetzungen zur hemmung der knochenschwund
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
ES2045319T3 (es) El uso del trifosfato de inosita en el tratamiento de da\os de tejido.
MX9301387A (es) Metodo y composicion para el tratamiento de osteoporosis.
PE20040961A1 (es) Composiciones farmaceuticas que comprenden epinastina para el tratamiento de enfermedades de la piel
ATE470449T1 (de) Förderer der hautwundheilung
DK88087A (da) Tricyklisk 5-(3-chlor-6-methyl-5,5-dioxo-6,11-dihydro-dibenzo-(c,f)-(1,2)-thiazepin-11-yl)-amino-pentansyrederivat, fremgangsmaade til fremstilling deraf og farmaceutiske midler indeholdende dem
McKowen et al. Infectious complications and cost-effectiveness of open resuscitation in the surgical intensive care unit after cardiac surgery
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
NZ235497A (en) Peptides (possibly related to hirudin) and pharmaceutical compositions for reducing blood coagulation
FI810509L (fi) Hetero-iminoprostacykliner
DK0506769T3 (da) Farmaceutisk præparat til behandling eller forebyggelse af retrovirus-infektioner
ATE454151T1 (de) Arzneimittel für nicht-cardiogene diastolische dysfunktion

Legal Events

Date Code Title Description
FC Application refused